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Purpose: Current in-hospital management of exacerbations of COPD is suboptimal, and patient 
outcomes are poor. The primary aim of this study was to evaluate whether implementation of 
a care pathway (CP) for COPD improves the 6 months readmission rate. Secondary outcomes 
were the 30 days readmission rate, mortality, length of stay and adherence to guidelines.
Patients and methods: An international cluster randomized controlled trial was performed 
in Belgium, Italy and Portugal. General hospitals were randomly assigned to an intervention 
group where a CP was implemented or a control group where usual care was provided. The 
targeted population included patients with COPD exacerbation.
Results: Twenty-two hospitals were included, whereof 11 hospitals (n=174 patients) were 
randomized to the intervention group and 11 hospitals (n=168 patients) to the control group. 
The CP had no impact on the 6 months readmission rate. However, the 30 days readmission 
rate was significantly lower in the intervention group (9.7%; 15/155) compared to the control 
group (15.3%; 22/144) (odds ratio =0.427; 95% confidence interval 0.222–0.822; P=0.040). 
Performance on process indicators was significantly higher in the intervention group for 2 of 
24 main indicators (8.3%).
Conclusion: The implementation of this in-hospital CP for COPD exacerbation has no impact 
on the 6 months readmission rate, but it significantly reduces the 30 days readmission rate.
Keywords: COPD, care pathway, readmission, quality improvement, cluster randomized 
controlled trial
Introduction
Exacerbations of COPD are a leading cause of hospital admissions worldwide. 
Thirty-five percent of COPD patients have at least 1 admission a year, with up to 30% 
readmitted within the 6 months after discharge.1–3 Adequate in-hospital management 
is expected to reduce readmission rates.4 Although several worldwide established 
guidelines are available for the management of COPD,2,5 the current in-hospital 
management of COPD exacerbations is suboptimal, and outcomes with regard to 
readmission and mortality are poor.6,7
Care pathways (CPs) are widely used for optimizing adherence to guidelines and 
improving outcomes.8–10 They are defined as “a complex intervention for the mutual 
decision making and organization of predictable care for a well-defined group of 
patients during a well-defined period”.11 Although COPD exacerbations are well 
suited to be treated in CPs, existing research on effectiveness is limited. Moreover, 
not one randomized study on COPD CPs has been reported up to date.12–15 As CPs 
are complex interventions that induce change at different levels of the organization, 
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cluster randomized controlled trials (CRCTs) should be used 
to study their impact.16
This trial is a CRCT on CP effectiveness launched by 
the European Pathway Association (E-P-A) in 2009.11 The 
primary aim of this study was to evaluate whether imple-
mentation of a CP improves the 6 months readmission rate 
for patients with a COPD exacerbation. Secondary outcomes 
were the 30 days readmission rate, mortality, length of stay 
and adherence to guidelines.
Patients and methods
study design and participants
A pragmatic CRCT17 was conducted, and the clusters included 
general hospitals out of Belgium, Ireland, Italy and Portugal, 
where patients hospitalized for a COPD exacerbation were 
cared for by a multidisciplinary team. Hospitals were random-
ized to either an intervention group, where a CP was devel-
oped and implemented, or a control group, where usual care 
was provided (Figure 1). Usual care means that team mem-
bers provide the same care during the study period as they 
were doing before implementation in the study. The study 
was registered as a CRCT at ClinicalTrials.gov (identifier: 
NCT00962468). Ethical approval was obtained on 3 levels. 
First, ethical approval was sought by the ethical committee of 
the research center at the country level. This included approval 
by the ethical committee of the coordinating center at Leuven 
University (identifier: ML5617), the National Committee 
of Data Protection for Portugal (6497/2011) and the ethical 
committee of the AOU Maggiore della Carità di Novara for 
Italy (625, 21/07/2011). Second, ethical approval was sought 
with regard to participation in the trial at the cluster level by 
the ethical committee of each of the participating hospitals 
(Table S1). Finally, individual written informed consent was 
obtained from all patients with regard to participation in the 
study and access to the patient record.
General hospitals could develop a CP when they provided 
written agreement to participate in the study. When hospitals 
were randomized into the control group, they agreed to not 
develop and implement a COPD CP within the time frame 
of the study. Eligibility criteria for patients were 1) hospital 
admission with COPD exacerbation as the primary diagnosis, 
2) hospitalized for at least 48 hours, 3) admitted in a ward 
where COPD exacerbations were usually treated, 4) able to 
understand and read the native language and 5) provision of 
written informed consent. Patients could be included in the 
study only once, specifically at their first admission during the 
study period. Patients were excluded 1) if already included 
in another study of which the measurements could influence 
the measurements or outcomes of this study or 2) if they 
needed invasive positive pressure ventilation at admission 
to the hospital.11
Enrollment of hospitals was done by the E-P-A, in close 
collaboration with the national E-P-A coordinator of each 
country. After consent, a study coordinator was appointed 
in each participating hospital.11
randomization and masking
Allocation concealment at team level was not possible and 
therefore general hospitals were stratified by country level, 
hospital type (teaching versus non-teaching), hospital size 
(,600 and $600 beds) and annual patient volume for 
COPD exacerbation (,300 patients and $300 patients)18,19 
and then randomly assigned to the intervention group or to 
the control group. The allocation sequence was computer 
generated by a principal investigator at the coordination 
center at Leuven University, using a random number list and 
statistical software (http://www.randomizer.org). Study coor-
dinators and teams were informed on their allocation after 
randomization. To minimize the risk for testing bias, the 
detailed data collection protocol was sent to the study 
,QWHUYHQWLRQ(YDOXDWLRQRQWKHTXDOLW\DQGRUJDQL]DWLRQRIFDUHEHIRUH&3LPSOHPHQWDWLRQ3URYLGLQJDVHWRILGHQWLILHGHYLGHQFHEDVHGNH\LQWHUYHQWLRQVRQLQKRVSLWDOPDQDJHPHQWRI&23'H[DFHUEDWLRQVWRHDFKPXOWLGLVFLSOLQDU\WHDP7UDLQLQJRISDWKZD\IDFLOLWDWRUVRQ&3GHYHORSPHQWDQGLPSOHPHQWDWLRQE\XVLQJWKHSKDVHSURWRFROEDVHGRQWKH'HPLQJ3'6$F\FOH
0HDVXUHPHQW&OLQLFDODQGWHDPDXGLW±3URFHVVLQGLFDWRUV±2XWFRPHLQGLFDWRUV±7HDPLQGLFDWRUV
0HDVXUHPHQW&OLQLFDODQGWHDPDXGLW±3URFHVVLQGLFDWRUV±2XWFRPHLQGLFDWRUV±7HDPLQGLFDWRUV
,QWHUYHQWLRQJURXS
&RQWUROJURXS
+RVSLWDOV
5DQGRPL]DWLRQEDVHGRQVWUDWLILFDWLRQFRXQWU\OHYHOKRVSLWDOW\SHKRVSLWDOVL]HDQGDQQXDOSDWLHQWYROXPHIRU&23'H[DFHUEDWLRQ
Figure 1 study overview.
Abbreviation: CP, care pathway.
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coordinator of each hospital just before the start of the data 
collection. Furthermore, a logbook was kept for included 
patients in order to be able to connect the patient identity to 
the study number. In addition, to check for selection bias, 
for each patient admitted with COPD exacerbation during 
the recruitment period but excluded, baseline characteristics 
and the reason for exclusion were reported in a logbook for 
excluded patients.
Finally, in order to prevent assessment bias, all data, 
except for the measurements at discharge, were collected by 
an external researcher outside the clinical team. At discharge, 
a structured interview of the patient by a team member was 
performed to collect information on previous home situation 
and therapy before admission, which did not imply any risk 
for bias of the measurements.
Intervention
In the intervention group, a CP was implemented at 
hospital-level CP, and the intervention was composed of 
3 active components (Figure 1).11 1) An evaluation on the 
quality and organization of care before CP implementation. 
In every hospital, a clinical audit was performed during a 
2- to 3-month period, 6 months before developing the CP. 
Hospitals received a feedback report describing their per-
formance compared to evidence-based guidelines and the 
performance of all other participating hospitals. The purpose 
of this feedback report was to help the hospitals in under-
standing the deficiencies in their actual organization of the 
care. This feedback report was discussed during a workshop, 
held before the start of the CP development. This workshop, 
as part of the intervention, was held before the start of the 
CP development and was attended by pneumologist, (head)
nurse, physiotherapists and/or pathway facilitator of each 
participating hospital. During this workshop, the purpose 
of the EQCP study was presented, and the feedback report 
and the key interventions were discussed. This workshop 
closed with the next steps of the study, and time plans were 
presented. 2) Providing a set of identified evidence-based 
key interventions20 on in-hospital management of COPD 
exacerbations to each multidisciplinary team. The set of 
key interventions were based on literature, an international 
Delphi study and consensus meeting with multidisciplinary 
expert panel.20 During the workshop, described earlier, these 
key interventions were presented and discussed. During the 
implementation phase, teaching sessions were organized by 
a pneumologist and a respiratory clinical nurse specialist 
concerning those key interventions for which teams expe-
rienced implementation difficulties, ie, administration of 
corticoid therapy, education on self-management strategies 
and inhalation therapy. Finally, slide kits were provided to the 
pathway facilitator of each hospital, ie, regarding administra-
tion of oxygen therapy, in order to support the facilitators in 
the education of their team members regarding the different 
key interventions. 3) Training of pathway facilitators on 
CP development and implementation by using the 7-phase 
protocol based on the Deming-Plan Do Study Act cycle.21 
For the development and implementation of the CP, the 
findings of the evaluation of the care process and the set of 
evidence-based key interventions were used. Meetings with 
the pathway facilitators were organized to further discuss 
the feedback reports and to address problems in implemen-
tation. Furthermore, a change expert supported change and 
exchange of knowledge and best practices.11,22 The teams 
developed a CP over a 6- to 8-month period.23 In the control 
group, patients received the usual care, and no intervention 
was developed or implemented before.
Measurement
The primary outcome was the 6 months readmission rate. 
Secondary outcomes included the 30 days readmission rate, 
the 30 days and the 6 months mortality rate, length of stay 
and results on 24 main process indicators, categorized in 
diagnostic, pharmacological and non-pharmacological man-
agement, respectively. Twelve of 24 main process indicators 
were built of 2 or more subcomponents. For the 30 days and 
the 6 months readmission rate, which refers to COPD-specific 
readmission, only patients alive at, respectively, the 30 days 
and the 6 months were included in the analyses.20 Addition-
ally, demographic and COPD-specific data were collected.
The measurement period started 2–3 months after the 
end of the implementation period.21 Data were collected by 
structured interviews performed by a team member at dis-
charge, patient questionnaires completed at discharge and 
30 days after discharge, structured telephone interviews at 
30 days and 6 months after discharge performed by the study 
coordinator and a patient record analysis after discharge of 
the patient, performed by the study coordinator, together with 
a clinician outside the care team. In each hospital, all data 
were collected centrally and subsequently provided to the 
national coordinators of all participating countries. Data input 
was performed in a central database at Leuven University 
and guided by using a rigorous data input protocol.
statistical analysis
Sample size calculation was performed according to standard 
criteria for CRCTs.11,24 Based on a number of 20 consecu-
tive admitted patients in each unit, 20 hospitals needed to 
be included in both the intervention and the control groups. 
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Briefly, the intracluster correlation coefficient (ICC) for the 
6 months readmission rate was estimated to be equal to 0.018, 
leading to a design effect of 1.342. Using standard 0.05 α error 
and assuming a reduction of 11% in the 6 months readmission 
rate (from 41% to 30%),25,26 a sample size of 398 patients per 
arm was required to obtain a statistical power of 0.80.11
A univariate analysis was carried out testing the baseline 
characteristics between intervention and control groups by 
using the chi-square test, Mann–Whitney U-test and inde-
pendent sample t-test for categorical, ordinal and continuous 
variables, respectively. The process indicators were analyzed 
by 2-level mixed-effects logistic regression model, accounting 
for the clustering effect. The outcome indicators are analyzed 
by using a 2-level mixed-effects logistic and linear regression 
model for categorical and continuous variables, respectively, 
accounting for the clustering effect. For the adjusted out-
comes, the significant variables (P,0.1), as determined by 
the univariate analysis and the intervention, were included in 
the final model. Multicollineairity was assessed.
Statistical significance was defined as a 2-sided P-value 
of 0.05. All analyses were intention to treat, performed by 
using R package lme4 (version 3.1.0) and MPlus 7.3 for 
ICC calculations.
Results
Initially, 65 hospitals were eligible for inclusion. After 
receiving the detailed study protocol, 22 hospitals decided 
to participate in the study. Of the 43 hospitals who did not 
take part in the study, 26 hospitals decided to not participate 
because they found the workload associated with the study 
too high. Furthermore, all 14 Irish hospitals dropped out 
because of reorganization of the Irish health care system and 
3 hospitals dropped out because of internal reorganization.
Regardless of the drop-out, by chance 11 hospitals were 
allocated to the intervention group and 11 hospitals to the 
control group. In total, 342 patients, 174 in the intervention 
group and 168 in the control group, were recruited. The 
Belgian hospitals included patients between October 2010 
and November 2011, while the Italian and Portuguese hospi-
tals included patients between January 2013 and April 2014. 
In the intervention group, respectively, 10 patients and 
1 patient were lost to follow-up at 30 days and 6 months after 
discharge, because of not reachable by the study coordinator. 
In the control group, respectively, 7 and 13 patients were lost 
to follow-up at 30 days and 6 months after discharge for the 
same reason (Figure 2).
With regard to patient characteristics, the groups were 
highly comparable except for COPD severity at admission 
(higher in control group, P=0.018), diabetes (higher in the 
control group, P=0.007) and low body mass index (more 
present in the intervention group, P=0.003). Also, although 
not significant, cardiac failure and hospitalization in the year 
before index admission were higher in the control group. 
At cluster level, both groups were comparable for type, size 
and annual volume of patients admitted with COPD exac-
erbation (Table 1).
The 6 months readmission rate was lower in the interven-
tion group (27.3%) compared to the control group (33.0%), 
though this result was not found statistically significant 
(adjusted odds ratio [OR] =0.642, 95% CI 0.347–1.188, 
P=0.158). Readmission rate at 30 days was statistically sig-
nificantly lower (9.7%) in the intervention group compared 
to the control group (15.3%) (adjusted OR =0.427, 95% 
CI 0.222–0.822) (Tables 2 and 3). No significant differences 
were found for the 30 days and the 6 months mortality rate 
and length of stay.
Results on the individual process indicators are presented 
in Table 4. Performance on the individual process indicators 
was significantly higher for only 2 of 24 main indicators 
(8.3%) and for 9 of 41 subcomponents (22.0%). The largest 
differences were determined for the main indicators regarding 
non-pharmacological management (range of improvements: 
0.7–45.9 percentage points). The mean adherence to the 
total of 24 measured process indicators was 59.4% (range: 
18.8%–94.7%) in the intervention group and 49.4% (range: 
11.8%–88.2%) in the control group (P=0.071). No patient 
received all the care they should receive.
Discussion
The implementation of this CP has no significant effect on the 
6 months readmission rate. However, the 30 days readmis-
sion rate was significantly lower in the intervention group 
(9.7%) compared to the control group (15.3%). Performance 
on process indicators was significantly higher in the interven-
tion group for 2 of 24 main indicators (8.3%) and for 9 of 41 
subcomponents (22.0%).
Before the launch of this study, only 5 national CRCTs 
on CPs had been conducted.23,27–30 This first international trial 
provides new knowledge on the design of a multicountry 
CRCT. In comparison to former pathway studies, 1) the 
impact of the CP on the care itself was comprehensively 
investigated, while earlier studies focused primarily on 
outcomes,12–15 2) training of teams was an active component 
of the intervention and 3) a clinical audit, as part of the 
intervention, allowed each hospital to focus on those key 
interventions that showed most room for improvement.21
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A weakness of the study is that 43 hospitals withdrew 
after randomization, which resulted in a smaller sample size 
than initially targeted. It is reasonable to assume that the 
lower power of the study may have led to a failure in detect-
ing statistically significant differences. The experience in 
this study is that a multicountry CRCT poses a major chal-
lenge due to standardization of the intervention in order to 
deliver the “same” intervention at the different sites, logistic, 
economic and cultural issues. These conditions should be con-
sidered carefully before starting an international CRCT. The 
study was underpowered, but it was decided not to increase 
the number of patients within the clusters because increasing 
the sample size per cluster does not increase power.31
Research on COPD CPs is very limited. Previous studies 
described positive effects on blood sampling, daily weight 
measurement, arterial blood gas measurement, referral to 
KRVSLWDOVDYDLODEOHIRUDQDO\VLVDWGD\VSDWLHQWVDYDLODEOHIRUDQDO\VLVRIGD\UHDGPLVVLRQUDWHSDWLHQWVDYDLODEOHIRUDQDO\VLVRIGD\PRUWDOLW\UDWH
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KRVSLWDOVDYDLODEOHIRUDQDO\VLVDWGD\VSDWLHQWVDYDLODEOHIRUDQDO\VLVRIGD\UHDGPLVVLRQUDWHSDWLHQWVDYDLODEOHIRUDQDO\VLVRIGD\PRUWDOLW\UDWH
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UHRUJDQL]DWLRQRIWKHKHDOWKV\VWHP KRVSLWDOVLQWHUQDOUHRUJDQL]DWLRQ
KRVSLWDOVZLWKGUHZIURPWKHVWXG\ KRVSLWDOVZRUNORDGRIVWXG\WRRKLJK KRVSLWDOV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KRVSLWDOVDYDLODEOHIRUDQDO\VLVDWPRQWKVSDWLHQWVDYDLODEOHIRUDQDO\VLVRIPRQWKUHDGPLVVLRQUDWHSDWLHQWVDYDLODEOHIRUDQDO\VLVRIPRQWKPRUWDOLW\UDWH
KRVSLWDOVLQFOXGHGLQDQDO\VLVSDWLHQWVLQFOXGHGLQDQDO\VLV$YHUDJHFOXVWHUVL]HQ UDQJH±
KRVSLWDOVUDQGRPL]HGWRLQWHUYHQWLRQJURXS
KRVSLWDOVUDQGRPL]HG
KRVSLWDOVUDQGRPL]HGWRFRQWUROJURXS
KRVSLWDOVLQFOXGHGLQDQDO\VLVSDWLHQWVLQFOXGHGLQDQDO\VLV$YHUDJHFOXVWHUVL]HQ UDQJH±
Figure 2 Participant flow at hospital and patient level.
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Table 2 results on outcome indicators
Intervention 
group
Control 
group
Difference unadjusted Difference adjusted
OR (95% CI) P-value ICC OR (95% CI) P-value
6 months readmission 38/139 (27.3) 38/115 (33.0) 0.817 (0.454–1.470) 0.500 0.015 0.642 (0.347–1.188) 0.158
30 days readmission 15/155 (9.7) 22/144 (15.3) 0.570 (0.223–1.450) 0.241 0.041 0.427 (0.222–0.822) 0.040
6 months mortality 18/157 (11.5) 18/134 (13.4) 0.822 (0.314–2.157) 0.691 0.065 0.611 (0.189–1.972) 0.410
30 days mortality 3/168 (1.8) 2/153 (1.3) 0.965 (0.192–4.840) 0.965 nC 0.880 (0.126–6.166) 0.898
length of stay 12.0 (10.5) 12.8 (12.4) 0.550 (0.021–14.284) 0.720 0.043 0.901 (0.015–53.049) 0.960
Notes: adjusted for COPD severity at admission, cardiac failure, diabetes, BMI and intervention–control group.
Abbreviations: BMI, body mass index; 95% CI, 95% confidence interval; ICC, intracluster correlation coefficient; NC, not possible to calculate; OR, odds ratio.
Table 1 Baseline characteristics of patients and hospitals
Intervention group 
(n=174)
Control group 
(n=168)
P-valuea
Individual level
age (years) 69.4 (10.8) 70.4 (9.7) 0.337
gender 0.645
Men 116/174 (66.7) 116/168 (69.0)
Women 58/174 (33.3) 52/168 (31.0)
COPD severity at admission 0.018
gOlD I: mild 8/171 (4.7) 12/154 (7.8)
gOlD II: moderate 55/171 (32.2) 29/154 (18.8)
gOlD III: severe 68/171 (39.8) 57/154 (37.0)
gOlD IV: very severe 40/171 (23.4) 56/154 (36.4)
Unknown 3 14
smoking status 0.879
no smoker 11/171 (6.4) 13/168 (7.7)
ex-smoker 87/171 (50.9) 86/168 (51.2)
active smoker 73/171 (42.7) 69/168 (41.1)
Unknown 3 0
hospitalization in the year 
before index admissionb
0.234
0 101/154 (65.6) 85/145 (58.6)
$1 53/154 (34.4) 60/145 (41.4)
Unknown 20 23
Charlson comorbidity index 0.160
#2 59/174 (33.9) 45/168 (26.8)
.2 115/174 (66.1) 123/168 (73.2)
Cardiac failurec 56/171 (32.7) 69/165 (41.8) 0.091
Unknown 3 3
Diabetesd 21/171 (12.3) 39/165 (23.6) 0.007
Unknown 3 3
BMI
,20 46/159 (28.9) 23/156 (14.7)
$20 113/159 (71.1) 133/156 (85.3) 0.003
Unknown 15 12
hospital level
Teaching hospitals 5/11 (45.5) 5/11 (45.5) 1.000
.600 beds 2/11 (18.2) 3/11 (27.3) 0.610
.300 patients admitted with 
COPD exacerbation per year
2/11 (18.2) 1/11 (9.1) 0.531
Notes: Data are mean (sD) or n/n (%). aChi-square test, Mann–Whitney U-test and independent sample t-test for categorical, ordinal and continuous variables, respectively. 
bIndex admission: first admission during the study, at point of inclusion. cIncludes heart failure, arrhythmia, valvular disease, acute myocardial infarction and ischemic heart 
disease. dIncludes diabetes uncomplicated and complicated.
Abbreviations: BMI, body mass index; gOlD, global Initiative for Obstructive lung Disease; sD, standard deviation.
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Table 3 Two-level mixed-effects regression model
6 months readmission 30 days readmission
OR (95% CI) P-value OR (95% CI) P-value
COPD severity at admission
gOlD I 1.0 (reference) – 1.0 (reference) –
gOlD II 0.652 (0.155–2.746) 0.560 0.304 (0.067–1.394) 0.252
gOlD III 0.724 (0.183–2.867) 0.645 0.220 (0.051–0.941) 0.041
gOlD IV 0.834 (0.204–3.408) 0.801 0.337 (0.079–1.436) 0.141
Cardiac failure 1.236 (0.655–2.333) 0.513 1.149 (0.511–2.580) 0.737
Diabetes 0.945 (0.395–2.259) 0.898 1.508 (0.540–4.210) 0.433
BMI 0.714 (0.363–1.405) 0.300 0.697 (0.289–1.686) 0.424
Main effect adjusted for 
(intervention–control group)
0.642 (0.347–1.188) 0.158 0.427 (0.222–0.822) 0.040
Abbreviations: BMI, body mass index; 95% CI, 95% confidence interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease; OR, odds ratio.
Table 4 results on process indicators: main level and subcomponent levela
Intervention group, 
n/N (%)
Control group, 
n/N (%)
P-value Difference between 
intervention and 
control group
Process indicators on diagnostic management
 1. Performance of ABG measurement during first 24 hours of admission 136/174 (78.2) 126/168 (75.0) 0.526 3.2
 2. Performance of chest X-ray during first 24 hours of admission 160/174 (92.0) 143/168 (85.1) 0.773 6.9
a. Performance of chest X-ray during hospitalization 172/174 (98.9) 164/168 (97.6) 0.445 1.3
b. Performance occurred within first 24 hours of admission 160/172 (93.0) 143/164 (87.2) 0.895 5.8
 3. Performance of electrocardiogram during first 24 hours of admission 134/174 (77.0) 121/168 (72.0) 0.847 5.0
a. Performance of electrocardiogram during hospitalization 161/174 (92.5) 149/168 (88.7) 0.442 3.8
b. Performance occurred within first 24 hours of admission 134/161 (83.2) 121/149 (81.2) 0.867 2.0
 4. sputum culture and antibiogram in patients with purulent sputum 
and/or before starting antibiotics
110/154 (71.4) 88/151 (58.3) 0.626 13.1
 5. Measurement of FeV1 during current hospitalization 123/174 (70.7) 102/168 (60.7) 0.248 10.0
Process indicators on pharmacological management
 6. Prescription of short-acting bronchodilators during hospitalization 160/174 (92.0) 113/168 (67.3) 0.116 24.7
 7. Prescription of long-acting bronchodilators during hospitalization 139/174 (79.9) 139/168 (82.7) 0.606 −2.8
 8. Prescription of 30–40 mg of oral prednisolone daily for 7–10 days 50/174 (28.7) 19/168 (11.3) 0.091 17.4
a. Systemic glucocorticosteroids prescribed during 
hospitalization
152/174 (87.4) 135/168 (80.4) ,0.001 7.0
b. Prescription of glucocorticosteroids for 7 days to maximum 
14 days starting at admission in patients in which glucocorticoids 
were prescribed
113/152 (74.3) 83/135 (61.5) 0.203 12.8
c.	Dose	of	glucocorticosteroids	prescribed	during	first	7	days	
of hospitalization was 30–40 mg in patients in which 
glucocorticoids were prescribed
134/152 (88.2) 93/135 (68.9) 0.022 19.3
d. Oral administration since hospitalization day 2 or earlier in 
patients in which glucocorticoids were prescribed
80/152 (52.6) 43/135 (31.9) 0.312 20.7
 9. Prescription of antibiotics 139/174 (79.9) 139/168 (82.7) 0.655 −2.8
Process indicators on non-pharmacological management
 10. administration of controlled oxygen therapy in patients hypoxemic 
during admission
44/47 (93.6) 39/42 (92.9) 0.996 0.7
 11. assessment of smoking status 161/174 (92.5) 153/168 (91.1) 0.970 1.4
 12. smoking cessation intervention in active smokers at admission 3/42 (7.1) 0/40 (0.0) nC 7.1
a. Providing of spoken information about quitting strategies 
by physician or nurse in active smokers at admission
23/42 (54.8) 10/40 (25.0) 0.030 29.8
b.	Providing	of	smoking	cessation	leaflet	in	active	smokers	at	
admission
15/42 (35.7) 1/40 (2.5) 0.049 33.2
(Continued)
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Table 4 (Continued)
Intervention group, 
n/N (%)
Control group, 
n/N (%)
P-value Difference between 
intervention and 
control groupa
c. Providing of quitting aids before discharge in active smokers 
at admission who wants to quit smoking by using quitting aids 
(patches, gum, medication)
9/16 (56.3) 3/9 (33.3) 0.277 23.0
d. referral to counseling in active smokers at admission who wants 
to quit smoking by counseling (individual/group)
2/3 (66.7) 1/4 (25.0) 0.880 41.7
e. Contacting of patient in the following month after discharge by the 
general practitioner, primary nurse or somebody of the hospital 
about his/her smoking or attempt to quit in active smokers at 
admission
6/42 (14.3) 4/40 (10.0) 0.726 4.3
 13.  Adequate education regarding inhaler therapy in patients in 
which inhaler therapy is prescribed
61/173 (35.3) 15/165 (9.1) 0.037 26.2
a. Providing of education regarding inhaler medication in patients in 
which inhaler therapy is prescribed
110/173 (63.6) 33/165 (20.0) 0.118 43.6
b. Providing of education regarding inhaler technique in 
patients in which inhaler therapy is prescribed
114/173 (65.9) 33/165 (20.0) 0.049 45.9
c. Providing of education regarding inhaler device in patients in which 
inhaler therapy is prescribed
109/173 (63.0) 37/165 (22.4) 0.171 40.6
d. Providing of a leaflet with explanation regarding inhaler therapy in 
patients in which inhaler therapy is prescribed
81/170 (47.6) 53/162 (32.7) 0.192 14.9
 14. education regarding home oxygen therapy in patients in which 
home oxygen is prescribed
14/52 (26.9) 0/64 (0.0) nC 26.9
a. Providing of education regarding oxygen source in patients 
in which home oxygen is prescribed
25/52 (48.1) 15/64 (23.4) 0.374 24.7
b. Providing of education regarding equipment (cannulae/mask) 
in patients in which home oxygen is prescribed
24/52 (46.2) 13/64 (20.3) 0.414 25.9
c. Providing of education regarding safety precautions in patients 
in which home oxygen is prescribed
24/52 (46.2) 8/64 (12.5) 0.481 33.7
d. Providing of spoken information regarding oxygen therapy in 
patients in which home oxygen is prescribed
25/50 (50.0) 16/62 (25.8) 0.241 24.2
e. Providing of a leaflet with explanation regarding oxygen therapy 
in patients in which home oxygen is prescribed
18/50 (36.0) 12/62 (19.4) 0.219 16.6
 15. Performance of revalidation tests during the past year (inclusive 
current hospitalization)
20/174 (11.5) 13/168 (7.7) 0.493 3.8
 16. referral to pulmonary revalidation during the past year 76/174 (43.7) 52/168 (31.0) 0.192 12.7
 17.  Nutritional assessment (BMI) 111/174 (63.8) 30/168 (17.9) 0.002 45.9
 18. nutritional management in patients with underweight 10/57 (17.5) 3/38 (7.9) 0.411 9.6
a. Referral to dietician in patients with underweight 27/57 (47.4) 5/38 (13.2) 0.015 34.2
b. Providing of nutritional advice in patients with 
underweight
21/57 (36.8) 4/38 (10.5) 0.040 26.3
c. Providing of nutritional supplement in patients with underweight 21/57 (36.8) 8/38 (21.1) 0.354 15.7
 19. nutritional management in patients with overweight 10/28 (35.7) 4/23 (17.4) 0.443 18.3
a. referral to dietician in patients with overweight 16/28 (57.1) 5/23 (21.7) 0.051 35.4
b. Providing of advice regarding weight loss in patients with 
overweight
14/28 (50.0) 6/23 (26.1) 0.372 23.9
 20. Patient received influenza vaccination within the past year 113/174 (64.9) 97/168 (57.7) 0.991 7.2
 21. Patient received pneumococcal vaccination within the past 5 years 66/174 (37.9) 85/168 (50.6) 0.076 −12.7
 22. aBg measurement 1 or 2 days prior to discharge in patients 
hypoxemic during a COPD exacerbation
22/51 (43.1) 20/46 (43.5) 0.921 −0.4
 23. Prescription of home oxygen therapy in patients with hypoxemia at 
discharge
3/5 (60.0) 4/15 (26.7) 0.566 33.3
a. Proportion of patients in which home oxygen is prescribed in 
patients who remain hypoxemic at discharge
3/5 (60.0) 7/15 (46.7) 0.879 13.3
b. Proportion of patients with indication for home oxygen therapy, 
in which home oxygen therapy was prescribed for at least 
16 hours a day in patients who remain hypoxemic at discharge
3/5 (60.0) 4/15 (26.7) 0.566 33.3
(Continued)
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rehabilitation, feelings of anxiety, readmission and in-hospital 
mortality. Due to limited statistical analysis and weak study 
design, the internal validity of results is limited.12–15 Our 
study confirmed that the implementation of a CP significantly 
reduces the 30 days readmission rate.32,33
Although the 30 days readmission rate was significantly 
lower in the intervention group, no differences were found 
for readmission rate at 6 months. The 6 months readmission 
was chosen as primary outcome, based on previous studies 
and expert opinion. However, during the study, it became 
clear that the outcomes at 30 days after discharge are highly 
associated with the in-hospital treatment, which was the 
focus of the CP intervention, while results at 6 months are 
mainly related to the nature of the disease and the quality of 
the outpatient and primary care. Therefore, for future studies 
on in-hospital CPs and readmission, it is recommendable to 
primarily focus on the 30 days readmission.2 Finally, accord-
ing to our results, ~6 of every 100 COPD patients treated 
according to the CP avoid a readmission at 30 days (number 
needed to treat: 17.0). Worldwide, based on the data of the 
WHO, this would result in a potential reduction of ~4 million 
readmissions.34
With regard to process indicators, only 2 of these results 
were statistically significant, and by implementing a CP, 
the mean adherence to the guidelines was higher in the 
intervention group compared to the control group, though this 
difference was not significant. However, even non-significant 
results on process indicators may provide valid information 
regarding quality of care. Indeed, existing clinical practice 
guidelines on management of COPD exacerbation, which 
are very congruent and continuously updated, recommend 
unambiguously that the evaluated processes should be 
performed in every patient who is hospitalized for COPD 
exacerbation, regardless of patient characteristics or con-
textual factors. It is important to notice that, despite large 
improvements on process indicators after CP implementation, 
a considerable number of processes, especially with regard 
to non-pharmacological management, remained suboptimal 
performed. The non-pharmacological management contains 
some key interventions regarding education concerning 
smoking cessation, inhaler therapy and home oxygen therapy. 
Guidelines recommend more education as education is seen 
as an important part in the treatment of patients with a COPD 
exacerbation.2 After implementing the CP, performance 
of education regarding inhaler therapy was significantly 
improved (9.1% in the control group and 35.3% in the inter-
vention group; Table 4). Although only 35.3% of the patients 
received education regarding inhaler therapy, while the other 
process indicators regarding education were even performed 
lower. So the care for patients with a COPD exacerbation 
is suboptimal performed, and therefore, continuous quality 
improvement will be needed in order to further optimize the 
care process for in-hospital management of COPD exacerba-
tion and to enhance sustainability of the improved results.35,36 
In addition, it is recommended that the team reconsiders the 
content of the pathway every 6 months.21 For instance, at the 
Table 4 (Continued)
Intervention group, 
n/N (%)
Control group, 
n/N (%)
P-value Difference between 
intervention and 
control groupa
 24. adequate discharge management 51/174 (29.3) 26/168 (15.5) 0.330 13.8
a. assessment of residence during current hospitalization 169/174 (97.1) 151/168 (89.9) 0.862 7.2
b. assessment of residential status within 3 days at admission 151/169 (89.3) 129/151 (85.4) 0.940 3.9
c. assessment of living status during current hospitalization 150/174 (86.2) 149/168 (88.7) 0.228 −2.5
d. assessment of living status within 3 days of admission 122/150 (81.3) 128/149 (85.9) 0.289 −4.6
e. assessment of social status during current hospitalization 153/174 (87.9) 145/168 (86.3) 0.501 1.6
f. assessment of social support within 3 days 115/153 (75.2) 124/145 (85.5) 0.199 −10.3
g. Providing of spoken explanation about home medication 88/174 (50.6) 78/167 (46.7) 0.855 3.9
h. Providing of discharge letter with explanation about further 
medication after discharge
100/174 (57.5) 83/167 (49.7) 0.473 7.8
i. Providing of letter with information about follow-up appointment 91/174 (52.3) 63/167 (37.7) 0.276 14.6
j. Planning of follow-up appointment at 4–6 weeks after 
discharge
151/174 (86.8) 95/167 (56.9) ,0.001 29.9
k. availability of letter for general practitioner in medical record 171/174 (98.3) 161/168 (95.8) 0.314 2.5
l. Support arranged at discharge if needed 25/32 (78.1) 10/23 (43.5) ,0.001 34.6
Prescription of nebulizer at the day of discharge 63/174 (36.2) 67/168 (39.9) 0.898 −3.7
Note: aResults in bold refer to significance.
Abbreviations: aBg, arterial blood gas; BMI, body mass index; FeV1, forced expiratory volume at 1 second; nC, not possible to calculate.
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beginning of 2014, the evidence concerning optimal duration 
of glucocorticoid therapy for acute exacerbations of COPD 
was changed.2,37
Follow-up research is needed to understand why and 
under which circumstances CPs work in terms of which 
active components in CPs underlie their effect and what is 
the role of contextual factors and multidisciplinary teamwork. 
Furthermore, an economic evaluation should be included to 
evaluate whether CPs also impact efficiency of care. Finally, 
in the context of the rising prevalence of COPD, CPs should 
also include transmural management and community-based 
treatment of COPD.2
Conclusion
The implementation of this in-hospital CP for COPD 
exacerbation significantly reduced the 30 days readmission 
rate. This first international cluster randomized trial on 
CPs shows that the evidence-based key interventions are 
better performed after implementation of a CP compared 
to usual care. Additional studies are needed to understand 
how CPs are working, what their effect is on long term 
and how they affect the organization of care for different 
patient groups.
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Table S1 list of participating hospitals that gave ethical approval for this study
asl aT
aO Mauriziano di Torino
aOU Maggiore della Carità di novara ward 1
aOU Maggiore della Carità di novara ward 2
aOU san luigi di Orbassano
asl al
asl TO1
asl VC
aZ sint – augustinus Wilrijk
aZ sint elizabeth Zottegem
aZ sint-Blasius Dendermonde
aZ sint-Jan aV Brugge
Centro hospitalar lisboa Central
heilig hart ziekenhuis roeselare – Menen campus Menen
heilig hart ziekenhuis roeselare Menen campus roeselare
hospital Distrital de Faro
Mariaziekenhuis Overpelt
rZ Jan Yperman Ieper
sint-elisabeth Ziekenhuis Turnhout
sint-Vincentius ziekenhuis, antwerpen
Virga Jesse Ziekenhuis hasselt
ZiekenhuisNetwerk Antwerpen campus Jan Palfijn 
Abbreviations: asl aT, azienda sanitaria locale di asti; aO, azienda Ospedaliera; aOU, azienda Ospedaliero Universitaria; asl al, azienda sanitaria locale della 
provincia di alessandria; asl VC, azienda sanitaria locale di Vercelli; asl TOI, azienda sanitaria locale Torino; aZ, algemeen ziekenhuis; rZ, regionaal ziekenhuis.
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